Category: Hepatitis b

According to the World Health Organization, over 290 million people worldwide are living with chronic hepatitis B (HBV), a potentially life-threatening liver infection. For those with compensated liver disease, VEMLIDY (tenofovir alafenamide, or TAF) offers a targeted and highly effective treatment option, with several key benefits, particularly in comparison to older-generation antivirals.

Clinical trials have shown that Vemlidy (tenofovir alafenamide, TAF) provides similar antiviral efficacy to Viread (tenofovir disoproxil fumarate, TDF) for chronic hepatitis B at a dose less than one-tenth that of Viread. This significant difference in dosage efficiency and safety profile is at the heart of the question: why is Vemlidy better than Viread?

Telbivudine, an antiviral agent once branded as Tyzeka in the United States, demonstrated significantly greater antiviral activity and less resistance compared to lamivudine in its initial clinical trials for treating chronic hepatitis B. This medication was developed to suppress the hepatitis B virus (HBV) and mitigate liver damage in infected individuals.